Abstract
The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale multinational consortium studies, it has become possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. From these genome-wide studies, it became clear that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription, but its broader consequences include maintaining the integrity of the genome and modulating immune response. Here, we describe the aberrant DNA methylation changes that take place in cancer and how they contribute to the disease phenotype. Further, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- AML:
-
Acute myeloid leukemia
- CGIs:
-
CpG islands
- CIMP:
-
CpG island methylator phenotype
- CpG:
-
Cytosine-guanine dinucleotide
- DNMT:
-
DNA methyltransferases
- DNMTi:
-
DNA methyltransferase inhibitor
- dsRNA:
-
Double-stranded RNA
- ERV:
-
Endogenous retrovirus
- GBM:
-
Glioblastoma multiforme
- MDS:
-
Myelodysplastic syndrome
- TCGA:
-
The Cancer Genome Atlas
- TSGs:
-
Tumor suppressor genes
References
Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69:4443–53. doi:10.1158/0008-5472.CAN-08-4025.
Alvarez-Nuñez F, Bussaglia E, Mauricio D, et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid. 2006;16:17–23. doi:10.1089/thy.2006.16.17.
Andreotti G, Karami S, Pfeiffer RM, et al. LINE1 methylation levels associated with increased bladder cancer risk in pre-diagnostic blood DNA among US (PLCO) and European (ATBC) cohort study participants. Epigenetics. 2014;9:404–15. doi:10.4161/epi.27386.
Aran D, Hellman A. DNA methylation of transcriptional enhancers and cancer predisposition. Cell. 2013;154:11–3. doi:10.1016/j.cell.2013.06.018.
Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 2013;14:R21. doi:10.1186/gb-2013-14-3-r21.
Baylin SB, Jones PA. A decade of exploring the cancer epigenome — biological and translational implications. Nucleus. 2011. doi:10.1038/nrc3130.
Bender CM, Gonzalgo ML, Gonzales FA, et al. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol. 1999;19:6690–8.
Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH roadmap epigenomics mapping consortium. Nat Biotechnol. 2010;28:1045–8. doi:10.1038/nbt1010-1045.
Bestor TH, Edwards JR, Boulard M. Notes on the role of dynamic DNA methylation in mammalian development. Proc Natl Acad Sci. 2015;112:6796–9. doi:10.1073/pnas.1415301111.
Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816. doi:10.1038/nature05874.
Bjornsson HT, Brown LJ, Fallin MD, et al. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst. 2007;99:1270–3. doi:10.1093/jnci/djm069.
Božić T, Lin Q, Frobel J, et al. DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia. Clini Epigenetics. 2015;7:116. doi:10.1186/s13148-015-0153-6.
Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77. doi:10.1016/j.cell.2013.09.034.
Bulger M, Groudine M. Functional and mechanistic diversity of distal transcription enhancers. Cell. 2011;144:327–39. doi:10.1016/j.cell.2011.01.024.
Calo E, Wysocka J. Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013;49:825–37. doi:10.1016/j.molcel.2013.01.038.
Chadwick LH. The NIH roadmap epigenomics program data resource. Epigenomics. 2012;4:317–24. doi:10.2217/epi.12.18.
Cheng JC, Yoo CB, Weisenberger DJ, et al. Preferential response of cancer cells to zebularine. Cancer Cell. 2004;6:151–8. doi:10.1016/j.ccr.2004.06.023.
Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol. 2006;101:403–10. doi:10.1016/j.ygyno.2005.10.034.
Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162:974–86. doi:10.1016/j.cell.2015.07.011.
Christman JK. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–95. doi:10.1038/sj.onc.1205699.
Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-Aza-2’-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010;9:1443–50. doi:10.1158/1535-7163.MCT-09-1048.
Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009;10:691–703. doi:10.1038/nrg2640.
Costello JF, Berger MS, Huang HS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996;56:2405–10.
Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9. doi:10.1038/nature12222.
Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers. 2007;23:105–12.
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44. doi:10.1038/nature08617.
De Carvalho DD, Sharma S, You JS, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell. 2012;21:655–67. doi:10.1016/j.ccr.2012.03.045.
De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A. 1996;93:7149–53.
Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007;48:403–7. doi:10.1002/pbc.20803.
Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006;38:1378–85. doi:10.1038/ng1909.
Ecsedi SI, Hernandez-Vargas H, Lima SC, et al. Transposable hypomethylation is associated with metastatic capacity of primary melanomas. Int J Clin Exp Pathol. 2013;6:2943–8.
Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2010;1:239–59. doi:10.2217/epi.09.33.DNA.
Ehrlich M, Lacey M. Epigenetic alterations in oncogenesis. Epigenetic Alterations Oncog Adv Exp 31 Med Biol. 2013;754:31–56. doi:10.1007/978-1-4419-9967-2.
ENCODE Project Consortium. The ENCODE (ENCyclopedia of DNA Elements) Project. Science. 2004;306:636–40. doi:10.1126/science.1105136.
ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74. doi:10.1038/nature11247.
Esteller M. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10:3001–7. doi:10.1093/hmg/10.26.3001.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74. doi:10.1038/nrg3074.
Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.
Fang F, Turcan S, Rimner A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011;3:75ra25. doi:10.1126/scitranslmed.3001875.
Fatemi M, Paul TA, Brodeur GM, et al. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer. 2014;120:172–80. doi:10.1002/cncr.28316.
Feinberg AP, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun. 1983;111:47–54. doi:10.1016/S0006-291X(83)80115-6.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32. doi:10.1016/S1470-2045(09)70003-8.
Ferguson-Smith AC. Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet. 2011;12:565–75. doi:10.1038/nrg3032.
Ferreira HJ, Heyn H, Moutinho C, Esteller M. CpG island hypermethylation-associated silencing of small nucleolar RNAs in human cancer. RNA Biol. 2012;9:881–90. doi:10.4161/rna.19353.
Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–67. doi:10.1016/j.ccr.2010.11.015.
Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst. 2008;100:940–9. doi:10.1093/jnci/djn176.
Gama-sosa MA, Slagel VA, Trewyn RW. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 1983;11:6883–94. doi:10.1093/nar/11.19.6883.
Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196:261–82.
Gorringe KL, Choong DY, Williams LH, et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia. 2008;10:1253–8.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Helbo A, Treppendahl M, Aslan D, et al. Hypermethylation of the VTRNA1-3 promoter is associated with poor outcome in lower risk myelodysplastic syndrome patients. Genes (Basel). 2015;6:977–90. doi:10.3390/genes6040977.
Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700–4.
Hill VK, Shinawi T, Ricketts CJ, et al. Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas. BMC Cancer. 2014;14:506. doi:10.1186/1471-2407-14-506.
Hinoue T, Weisenberger DJ, Lange CPE, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271–82. doi:10.1101/gr.117523.110.
Hitchins MP, Wong JJL, Suthers G, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007;356:697–705. doi:10.1056/NEJMoa064522.
Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41:178–86. doi:10.1038/ng.298.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28. doi:10.1038/nrg816.
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484–92. doi:10.1038/nrg3230.
Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92. doi:10.1016/j.cell.2007.01.029.
Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–7. doi:10.1038/5947.
Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet. 2009;10:805–11. doi:10.1038/nrg2651.
Juo Y-Y, Gong X-J, Mishra A, et al. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics. 2015;7:215–35. doi:10.2217/epi.14.73.
Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res. 2005;65:11236–40. doi:10.1158/0008-5472.CAN-05-2959.
Karami S, Andreotti G, Liao LM, et al. LINE1 methylation levels in pre-diagnostic leukocyte DNA and future renal cell carcinoma risk. Epigenetics. 2015;10:282–92. doi:10.1080/15592294.2015.1006505.
Kasinathan S, Henikoff S. 5-Aza-CdR delivers a gene body blow. Cancer Cell. 2014;26:449–51. doi:10.1016/j.ccell.2014.09.004.
Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069–78. doi:10.1038/nbt.1678.
Kelly TK, Liu Y, Lay FD, et al. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res. 2012;22:2497–506. doi:10.1101/gr.143008.112.
Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839–43.
Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472–9. doi:10.1038/nature12750.
Kuang Y, El-Khoueiry A, Taverna P, et al. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol. 2015;9:1799–814. doi:10.1016/j.molonc.2015.06.002.
Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44:1236–42. doi:10.1038/ng.2443.
Kulis M, Queirós AC, Beekman R, MartÃn-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta Gene Regul Mech. 2013;1829:1161–74. doi:10.1016/j.bbagrm.2013.08.001.
Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253–66. doi:10.1038/nrc1045.
Lay FD, Liu Y, Kelly TK, et al. The role of DNA methylation in directing the functional organization of the cancer epigenome. 2015:1–11. doi:10.1101/gr.183368.114.Freely.
Lee K-S, Park J-L, Lee K, et al. nc886, a non-coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in human gastric cancer. Oncotarget. 2014;5:3944–55.
Levenson VV. DNA methylation as a universal biomarker. Expert Rev Mol Diagn. 2010;10:481–8. doi:10.1586/erm.10.17.
Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993;366:362–5. doi:10.1038/366362a0.
Li H, Chiappinelli KB, Guzzetta AA, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014a;5:587–98.
Li J, Huang Q, Zeng F, et al. The prognostic value of global DNA hypomethylation in cancer: a meta-analysis. PLoS One. 2014b;9:e106290. doi:10.1371/journal.pone.0106290.
Li X, Yao X, Wang Y, et al. MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features. PLoS One. 2013;8:e59064. doi:10.1371/journal.pone.0059064.
Liang G, Chan MF, Tomigahara Y, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002;22:480–91. doi:10.1128/MCB.22.2.480.
Licht JD. DNA Methylation Inhibitors in cancer therapy: the immunity dimension. Cell. 2015;162:938–9. doi:10.1016/j.cell.2015.08.005.
Lin JC, Jeong S, Liang G, et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell. 2007;12:432–44. doi:10.1016/j.ccr.2007.10.014.
Lou S, Lee H-M, Qin H, et al. Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation. Genome Biol. 2014;15:408. doi:10.1186/s13059-014-0408-0.
Lu J, Song G, Tang Q, et al. IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF- k B signaling. J Clin Invest. 2015;125:1–18. doi:10.1172/JCI78437.Iroquois.
Mair B, Kubicek S, Nijman SMB. Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends Pharmacol Sci. 2014;35:136–45. doi:10.1016/j.tips.2014.01.001.
Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008;454:766–70. doi:10.1038/nature07107.
Mikkelsen TS, Ku M, Jaffe DB, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007;448:553–60.
Moen EL, Stark AL, Zhang W, et al. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther. 2014;13:1334–44. doi:10.1158/1535-7163.MCT-13-0924.
Nagarajan RP, Zhang B, Bell RJA, et al. Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res. 2014;24:761–74. doi:10.1101/gr.164707.113.
Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510–22. doi:10.1016/j.ccr.2010.03.017.
Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57. doi:10.1016/S0092-8674(00)81656-6.
Oki Y, Aoki E, Issa J-PJ. Decitabine – bedside to bench. Crit Rev Oncol Hematol. 2007;61:140–52. doi:10.1016/j.critrevonc.2006.07.010.
Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14:341–56. doi:10.1038/nrm3589.
Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011;473:394–7.
Pessia E, Makino T, Bailly-Bechet M, et al. Mammalian X chromosome inactivation evolved as a dosage-compensation mechanism for dosage-sensitive genes on the X chromosome. Proc Natl Acad Sci U S A. 2012;109:5346–51. doi:10.1073/pnas.1116763109.
Pfeifer GP. p53 mutational spectra and the role of methylated CpG sequences. Mutat Res. 2000;450:155–66. doi:10.1016/S0027-5107(00)00022-1.
Pontier DB, Gribnau J. Xist regulation and function explored. Hum Genet. 2011;130:223–36. doi:10.1007/s00439-011-1008-7.
Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of wilms tumor. JNCI J Natl Cancer Inst. 2001;93:1698–703. doi:10.1093/jnci/93.22.1698.
Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552–6.
Rhee I, Jair KW, Yen RW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature. 2000;404:1003–7. doi:10.1038/35010000.
Roulois D, Loo Yau H, Singhania R, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162:961–73. doi:10.1016/j.cell.2015.07.056.
Saied MH, Marzec J, Khalid S, et al. Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats. PLoS One. 2012;7:e33213. doi:10.1371/journal.pone.0033213.
Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9:435–43. doi:10.1016/j.ccr.2006.04.020.
Sakai T, Toguchida J, Ohtani N, et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet. 1991;48:880–8.
Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev. 2012;22:50–5. doi:10.1016/j.gde.2012.02.008.
Schmelz K, Wagner M, Dörken B, Tamm I. 5-Aza-2’-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683–95. doi:10.1002/ijc.20797.
Sharma S, De Carvalho DD, Jeong S, et al. Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet. 2011;7, e1001286. doi:10.1371/journal.pgen.1001286.
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27–36. doi:10.1093/carcin/bgp220.
Shen H, Laird PW. Interplay between the cancer genome and Epigenome. Cell. 2013;153:38–55. doi:10.1016/j.cell.2013.03.008.
Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599–612. doi:10.1038/nrc3343.
Shiohama Y, Ohtake J, Ohkuri T, et al. Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells. Immunol Lett. 2014;158:175–82. doi:10.1016/j.imlet.2014.01.004.
Silber JR, Bobola MS, Blank A, Chamberlain MC. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta. 2012;1826:71–82. doi:10.1016/j.bbcan.2011.12.004.
Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14:204–20. doi:10.1038/nrg3354.
Søes S, Daugaard IL, Sørensen BS, et al. Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. Oncoscience. 2014;1:367–74.
Srivastava P, Paluch BE, Matsuzaki J, et al. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10:237–46. doi:10.1080/15592294.2015.1017198.
Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8–13. doi:10.1002/ijc.23607.
Su S-F, de Castro Abreu AL, Chihara Y, et al. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. 2014;20:1978–89. doi:10.1158/1078-0432.CCR-13-2637.
Taniguchi T, Sullivan MJ, Ogawa O, Reeve AE. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc Natl Acad Sci U S A. 1995;92:2159–63.
TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15. doi:10.1038/nature10166.
Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Poznań, Poland). 2015;19:A68–77. doi:10.5114/wo.2014.47136.
Toyota M. Methylation profiling in acute myeloid leukemia. Blood. 2001;97:2823–9. doi:10.1182/blood.V97.9.2823.
Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.
Treppendahl MB, Qiu X, Søgaard A, et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012;119:206–16. doi:10.1182/blood-2011-06-362541.
Tsai H-C, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430–46. doi:10.1016/j.ccr.2011.12.029.
Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483:479–83. doi:10.1038/nature10866.
Vrba L, Garbe JC, Stampfer MR, Futscher BW. A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics. 2015;10:1074–83. doi:10.1080/15592294.2015.1106673.
Wang J, Chen H, Fu S, et al. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol. 2011;47:601–8. doi:10.1016/j.oraloncology.2011.05.003.
Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113–20. doi:10.1038/ng.2764.
Weisenberger DJ. Characterizing DNA methylation alterations from the cancer genome atlas. J Clin Invest. 2014;124:17–23. doi:10.1172/JCI69740.
Weisenberger DJ, Liang G. Contributions of DNA methylation aberrancies in shaping the cancer epigenome. Transl Cancer Res. 2015;4:219–34. doi:10.3978/j.issn.2218-676X.2015.05.01.
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93. doi:10.1038/ng1834.
Wolff EM, Byun H-M, Han HF, et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010;6:e1000917. doi:10.1371/journal.pgen.1000917.
Wrangle J, Wang W, Koch A, et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget. 2013;4:2067–79.
Wu MS, Wang HP, Lin CC, et al. Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma. Cancer Lett. 1997;120:9–14.
Yamazaki J, Issa J-PJ. Epigenetic aspects of MDS and its molecular targeted therapy. Int J Hematol. 2013;97:175–82. doi:10.1007/s12185-012-1197-4.
Yang X, Han H, De Carvalho DD, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26:577–90. doi:10.1016/j.ccr.2014.07.028.
Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010;31:536–46. doi:10.1016/j.tips.2010.08.001.
Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68:8954–67. doi:10.1158/0008-5472.CAN-07-6088.
Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997;13:335–40.
Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2’-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007;67:6400–8. doi:10.1158/0008-5472.CAN-07-0251.
You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22:9–20. doi:10.1016/j.ccr.2012.06.008.
Zarnett OJ, Sahgal A, Gosio J, et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA Neurol. 2015;72:589–96. doi:10.1001/jamaneurol.2014.3739.
Acknowledgment
The work in the Liang laboratory has been supported in part by the generous contribution of George and Vicky Joseph.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lakshminarasimhan, R., Liang, G. (2016). The Role of DNA Methylation in Cancer. In: Jeltsch, A., Jurkowska, R. (eds) DNA Methyltransferases - Role and Function. Advances in Experimental Medicine and Biology, vol 945. Springer, Cham. https://doi.org/10.1007/978-3-319-43624-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-43624-1_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43622-7
Online ISBN: 978-3-319-43624-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.